To assess how a patient with pulmonary arterial hypertension (PAH) is faring on therapy, look at the right heart, said Anjali ...

mitochondrial abnormalities and thrombosis are the dominant underlying pathobiologic processes of pulmonary arterial hypertension (PAH). In addition to conventional and supportive therapies ...

Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a serious condition that can impair blood flow ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

The PAH Initiative is hosting a video event in May to provide information about exercise benefits for PAH patients.

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the likelihood of major morbidity and mortality by 76% in the Phase III ZENITH trial.

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...